PubMed Health⌕ Search

Biomedical subjects

M G Glezer

Publications and source records attributed to M G Glezer.

At least 19 recordsLinked to original sources
PubMed2006

[The results of the POLONEZ study in Russia].

AIM: To define efficacy and safety of enarenal in patients with arterial hypertension (AH). MATERIAL AND METHODS: A total of 235 physicians from 13 towns of Russia and 4291 patients aged 30-70 years with AH of the first-second degree (60% women) participated in the trial. Patients with AH of the second degree were older, more frequently had obesity, diabetes mellitus, hyperlipidemia. RESULTS: Target blood pressure (TBP) was achieved in 69.5% patients. The target was more frequently achieved in AH of the first degree (87.6%) than of the second (51.4%), in the first degree AH it was achieved with the same frequency in men and women. In AH of the second degree the success with TBP achievement was more frequent in men. Obesity decreased treatment efficacy only in women (TBP was achieved in 88.3% and 79.6% normal and obese women, respectively. Smoking had no effect on the treatment efficacy. In diabetes mellitus systolic blood pressure target (< 140 mm Hg) was seen in 54.2%, < 130 mm Hz--in 28.6%, by diastolic pressure (< 90 mm Hz)--in 88% patients, < 80 mm Hg--in 57%. The response was evaluated according to 5-score scale (from bad to good). The treatment improved the condition of the patients from 2.83 to 3.59 scores after 4 weeks of therapy and to 4.04 after 8 weeks of therapy. Side effects were not registered in 77.6% patients, only 1.9% patients discontinued the drug because of toxicity. CONCLUSION: Enarenal, generic of enalapril, demonstrated efficacy comparable to that of the other ACE inhibitors, good tolerance and is recommended for treatment of hypertension.

Adult↗
PubMed2005

[Clinicogenetic aspects of carbohydrate metabolism disorders and efficacy of their correction with moxonidine and metformine in patients with arterial hypertension].

AIM: To study effects of monotherapy with moxonidine and metformine on metabolic parameters in hypertensive patients with carbohydrate dysbolism (CD) regarding polymorphic markers of genes PPARalpha, PPARgamma and IRS type 1 and 2. MATERIAL AND METHODS: A total of 83 patients (31 male and 52 female patients aged 40-75 years) with untreated arterial hypertension stage I, obesity and CD (by glucose tolerance test) entered the trial. The patients were randomized into two groups. Patients of group I (n=42) received moxonidin in a dose 0.4 mg/day, of group 2 (n=41)--metformin in a dose 1000 mg/day. Measurement of arterial pressure, blood count and biochemistry, oral test for glucose tolerance with glucose and insulin measurement before meal and 1, 2 and 3 hours later was made initially and on the treatment week 16 Genotypes of polymorphic markers of genes PPARA, PPARG2, IRS1 and IRS2 were defined in all the patients. RESULTS: Changes in basic hemodynamic and metabolic indices in therapy with moxonidine depending on polymorphic markers of genes PPARA, PPARG2, IRS1 and IRS2 in patients with AH and CD showed that G allele PPARG2 is associated with greater weight loss, G allele PPARA--with weight loss, C allele PPARA--with maximal fall of diastolic blood pressure. CONCLUSION: Genetic factors participate in development of metabolic disturbances in hypertensive patients, obesity and CD and determine treatment efficacy in each individual patient.

Adult↗
PubMed2005

[Moexipril influence on quality of life in postmenopausal women with arterial hypertension].

AIM: To evaluate a hypotensive effect and metabolic neutrality and safety of ACE inhibitor moexipril in postmenopausal women with arterial hypertension (AH), influence on quality of life. MATERIAL AND METHODS: Thirty two hypertensive postmenopausal women (age 63.1 +/- 0.8 years) received moexipril for 4 months. The history of AH was 10.4 +/- 2.3 years, on the average. After a free of drugs week moexipril was given in a dose 7.5 mg/day with titration to 15 mg in 2 weeks and addition (if the target pressure was not achieved) of hydrochlorothiaside in a dose 12.5 mg. The examination included 24-h monitoring of blood pressure, estimation of microalbuminuria (MAU), endothelial function and blood biochemistry. Initially and after 4 weeks of the treatment quality of life was assessed (scales SF-36 and EuroQol). RESULTS: The initial level of office BP was 164.33/94.50 mm Hg, in 3 months a target level was achieved (136/84 mm Hg). It persisted for the next month. Moexipril corrected endothelial function and vascular elasticity in all the patients. MAU fell from 28.28 to 8.10 mg/l. Quality of life improved. Lipid and carbohydrate changes were not registered. CONCLUSION: Moexipril has a hypotensive and nephroprotective effects, improves endothelial function and quality of life in hypertensive postmenopausal women.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed2003

[Safety of exercise and dobutamine stress echocardiography (results of 2383 tests)].

AIM: To elucidate complications and unfavorable side effects of diagnostic exercise and dobutamine stress echocardiography. MATERIAL: Results of exercise (n=1969) and dobutamine (n=414, 34% with the use of atropine) stress echocardiography conducted in 2 centers for diagnosis of coronary heart disease. Mean age of patients 54,4+/-9,4 years. RESULTS: There were no deaths or life threatening complications. Disturbances of cardiac rhythm and conduction (31% during exercise and 61% during dobutamine stress tests) were most frequent events. One of 13 exercise and of 5 dobutamine stress tests was stopped because of complications or side effects. Of 15 cases of ventricular tachycardia and 16 of hypotension (lowering of blood pressure by 20 mm Hg) 9 and 13, respectively, occurred during dobutamine tests. There were differences between centers in frequency of atropine use during dobutamine tests and therapy of stress induced chest pain. CONCLUSION: The data confirmed that both exercise and dobutamine/atropine stress echocardiography could be safely used in diagnosis of coronary heart disease.

Arrhythmias, Cardiac↗
PubMed2002

[Acute coronary syndrome without elevation of the ST segment: prognostic significance of determining the levels of troponin I and CPK-MBmass].

AIM: To assess diagnostic and prognostic role of CPK-MBmass and troponin I(TnI) in patients with acute coronary syndrome without persistent ST segment elevation (ACS). MATERIAL AND METHODS: Standard laboratory and device tests, measurements of CPK-MBmass and TnI levels at admission, 12 and 24 hours after hospitalization were performed in 51 ACS patients (33 men, 18 women, mean age 63 +/- 8.2 years). Early and late (1 month and 6, 12 months after hospitalization, respectively) complications were studied. RESULTS: The analysis of the immediate outcomes has revealed that treatment brought about stabilization of the condition in 45 (88.2%) patients, 6 patients had myocardial infarction within a month since the disease onset, one patient died. Late MI developed in 6 patients. For 6 months 2 more patients died. One patient died in the following 6 months. Thus ACS points to adverse 1-month prognosis in 12 and 1-year prognosis in 23.5% patients. TnI levels and CPK-MBmass are sensitive and specific for an adverse outcome in 91.7 and 100%, 82 and 89.7%, respectively. A predictive value for positive outcomes was 61.1 and 75%, respectively, for negative results 96.9 and 100%, respectively. CONCLUSION: Estimation of CPK-MBmass and TnI is essential in diagnosis of non-Q-wave MI and is predictable in relation to both short- and long-term prognosis.

Acute Disease↗
PubMed1995

[The clinical efficacy of the first Russian angiotensin-converting enzyme inhibitor methiopril in patients with heart failure].

Changes in central hemodynamics as recorded by tetrapolar rheography were investigated in 90 coronary heart disease (CHD) patients with circulatory insufficiency (CI) receiving methiopril. Relevant clinical response was registered in 94%, hemodynamic in 83% of patients. Those with CI stage IIA and IIB benefited more. Arterial pressure went down significantly only in CHD patients with arterial hypertension. Tachycardia patients showed a reduction in pulse rate absent in bradycardia. Cardiac output increased at the expense of low afterload. Efficient doses averaged 300 mg/day.

Aged↗
PubMed1995

[Clinical pharmacokinetics of fluorazole].

The ftorazole pharmacokinetics was studied in 14 patients after the oral administration of 40 and 80 mg as a single dose. The ftorazole concentrations in the serum specimens sampled within 8 hours were determined by GLC with an electron-capture detector. A pronounced variability was inherent in the individual concentration-time profiles: the mean values of the serum peak concentrations (Cmax) following the 40 and 80 mg dosing were 30-119 and 55-195 ng/ml respectively. Nonetheless, a dose-proportional increasing of the areas under the concentration-time curve (AUC) was observed. The mean values (SD) of the AUC related to the dose, absorption lag-time, time for reaching Cmax, the Cmax/AUC ratio as an index of the absorption rate, the elimination half-life and mean residence time were 6.64 (2.98) (ng.h/ml), 0.31 (0.17) h, 1.17 (0.55) h, 0.26 (0.05) h-1, 2.40 (0.70) h and 3.06 (0.28) h respectively. The data obtained are indicative of the ftorazole pharmacokinetics linearity in humans.

Adolescent↗
PubMed1992

[The effect of quinidine monotherapy and combined therapy with digoxin on the central hemodynamics in patients with heart rhythm disorders].

The study was undertaken to examine 84 patients mainly with coronary heart disease and various cardiac arrhythmias. Quinidine monotherapy was found to normalize heart rate depending on its baseline values: it reduced heart rate in tachycardias and increased it in bradycardia. In patients with severe myocardial damage, especially in hypertension, quinidine decreased cardiac index, whereas total peripheral resistance increased. With quinidine, systolic pressure, stroke and cardiac indices showed a more decrease, whereas diastolic pressure and total peripheral resistance displayed a more increase in the standing position. Supplement of digoxin corrected negative quinidine-induced hemodynamic changes and orthostatic failures.

Anti-Arrhythmia Agents↗
PubMed1992

[Evaluation of antianginal effects of running pulse magnetic field and drug therapy on the physical working capacity and hemodynamics in patients with stable angina pectoris].

The effects of the running pulse magnetic field, antianginal drug therapy and their combinations on the physical capacity were compared in 60 patients with Functional Classes I-III stable angina pectoris. Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.

Adult↗